Holen Sie sich die Stockscreener-App
79.76
10.01%
7.26
Schlusskurs vom Vortag:
$72.50
Offen:
$73.71
24-Stunden-Volumen:
13.49M
Relative Volume:
1.90
Marktkapitalisierung:
$31.65B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-3.19B
KGV:
-9.7911
EPS:
-8.1462
Netto-Cashflow:
$-1.60B
1W Leistung:
+33.49%
1M Leistung:
+74.76%
6M Leistung:
+158.46%
1J Leistung:
+163.41%
1-Tages-Spanne:
$73.68
$81.40
1-Wochen-Bereich:
$59.23
$81.40
52-Wochen-Spanne:
$22.28
$81.40
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
79.76 | 27.79B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna COVID-19 Vaccine SpikevaxCompany bets on booster demand in US clinics - AD HOC NEWS
Why Moderna Is Today’s Top S&P 500 Stock - Barron's
The Spikevax Bivalent Original/Omicron COVID-19 VaccineModerna Inc. targets booster demand in the - AD HOC NEWS
Moderna Stock’s Short Squeeze Fades: 3 Key Support Levels to Watch - Investing.com
Short Squeeze Alert—Moderna Stock Surges on New Strategy - MarketBeat
Pictet Asset Management Holding SA Has $32.79 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna (MRNA) Chief Commercial Officer files baseline Form 3 insider statement - Stock Titan
Is Moderna Stock a No-Brainer Buy After a Key FDA Win? - The Globe and Mail
Moderna Inc. mRESVIA targets older adults with a one-dose RSV shot - AD HOC NEWS
ETFs Investing in Moderna, Inc. Stocks - TradingView
mRNA-1273 Linked to Lower COVID-19 Risk Than NVX-CoV2705 - Infectious Disease Advisor
Moderna: Raising Fair Value Estimate Following Science Day That Supports Oncology Pipeline - Morningstar
Moderna Is Applying MRNA Technology in Vaccines, but Also Cancer and Rare Disease Therapies - Morningstar
MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines - TradingView
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
MRNA Stock Spikes as Moderna Shares mRNA Pipeline Update - Yahoo Finance
Stock Of The Day: Will The Moderna Rally Continue? - Benzinga
Moderna (MRNA) Stock Soars 13% on Groundbreaking CAR-T Program Announcement - Blockonomi
Moderna (NASDAQ:MRNA) surge puts stock above most analyst targets ahead of FDA review - TechStock²
Patton Fund Management Inc. Has $4.49 Million Stake in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (MRNA) Stock Analysis: Evaluating the 260% Revenue Growth Amidst a Volatile Market - DirectorsTalk Interviews
Moderna Stock Jumps 12% as Pipeline Reset Puts Aug. 5 FDA Catalyst in Focus - FXLeaders
MRNA Stock Rallies Over 40% In June: Moderna Bets Its Future On Cancer, Autoimmune Disease And AI-Powered mRNA - Stocktwits
Moderna | History, Innovation, Challenges, & Facts - Encyclopedia Britannica
Moderna (NASDAQ:MRNA) price targets draw attention as shares rally into short holiday week - TechStock²
Moderna (MRNA) Stock Soars 13% on In Vivo CAR-T Breakthrough and Flu Vaccine Progress - Blockonomi
SG Americas Securities LLC Sells 27,930 Shares of Moderna, Inc. $MRNA - MarketBeat
The mRESVIA from Moderna Inc.RSV protection moves beyond Covid - Ad-hoc-news.de
S&P 500 ends lower; chips tumble and Moderna rallies - Yahoo Finance
MRNA Stock Surges As Flu Win And Pipeline Shift Grab Attention - timothysykes.com
Wall Street ends mixed; chips tumble and Moderna rallies - marketscreener.com
Trending: Netflix stock bounces back, Moderna surges post–investor day, ON Semi plummets - Yahoo Finance
Moderna stock soars as cancer pipeline and CAR-T push ignite optimism - Invezz
MRNA Maintained by Piper Sandler -- Price Target Raised to $77.0 - GuruFocus
Moderna Shares Up on New Research Efforts for Autoimmune Disorder - WSJ
Wall Street mixed as Moderna rallies and chips tumble - marketscreener.com
Moderna (MRNA) Shares Surge 15% Following Major Business Update - GuruFocus
Moderna stock soars 15% as bulls cheer drug pipeline update: Next stop $75? - MSN
Moderna (NASDAQ:MRNA) Reaches New 12-Month HighHere's Why - MarketBeat
Moderna (MRNA) Sees 14.2% Surge, Reaches $68.23 - GuruFocus
Moderna (NASDAQ:MRNA) gains $3.3 billion after CAR-T update - TechStock²
MRNA Stock Jumps As Flu Win And Pipeline Story Heat Up - StocksToTrade
Moderna jumps 12% after investor day - Breakingthenews.net
Moderna highlights expanding mRNA platform at Science Day - Clinical Trials Arena
Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer? - 24/7 Wall St.
MRNA Stock Jumps As Flu Win And Pipeline Reset Ignite Momentum - timothysykes.com
Moderna stock hits 52-week high at $67.78 By Investing.com - Investing.com Canada
Moderna stock hits 52-week high at $67.78 - Investing.com
Moderna (MRNA) Sees 8.7% Gain, Closing at $64.95 - GuruFocus
Piper Sandler raises Moderna stock price target on pipeline progress - Investing.com
Piper Sandler raises Moderna stock price target on pipeline progress By Investing.com - Investing.com Canada
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moderna Inc-Aktie (MRNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hoge Stephen | President |
Jun 15 '26 |
Option Exercise |
19.15 |
53,336 |
1,021,384 |
1,537,184 |
| Hoge Stephen | President |
Jun 15 '26 |
Sale |
51.37 |
53,336 |
2,739,870 |
1,483,848 |
2.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):